Patents by Inventor Erez M. Bublil

Erez M. Bublil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OPTIMIZATION OF ENZYME REPLACEMENT THERAPY FOR TREATMENT OF HOMOCYSTINURIA
    Publication number: 20230039591
    Abstract: The present invention provides a method of PEGylating a human truncated cystathionine ?-synthase protein containing a mutation of a cysteine to a serine at amino acid position 15 (htCBS C15S). The htCBS C15S was PEGylated with one of 5 kDa, 10 kDa, or 20 kDa NHS ester PEG molecules. In-process monitoring of the PEGylation process was used in the method to reduce levels of unPEGylated htCBS C15S and htCBS C15S with insufficient PEGylation. Administration of the PEGylated htCBS C15S had efficacy throughout the course of treatment for homocystinuria.
    Type: Application
    Filed: April 5, 2022
    Publication date: February 9, 2023
    Inventors: Tomas Majtan, Jan P. Kraus, Erez M. Bublil, Frank Glavin, Marcia Sellos-Moura
  • Optimization of enzyme replacement therapy for treatment of homocystinuria
    Patent number: 11324811
    Abstract: The present invention provides a method of PEGylating a human truncated cystathionine ?-synthase protein containing a mutation of a cysteine to a serine at amino acid position 15 (htCBS C15S). The htCBS C15S was PEGylated with one of 5 kDa, 10 kDa, or 20 kDa NHS ester PEG molecules. In-process monitoring of the PEGylation process was used in the method to reduce levels of unPEGylated htCBS C15S and htCBS C15S with insufficient PEGylation. Administration of the PEGylated htCBS C15S had efficacy throughout the course of treatment for homocystinuria.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: May 10, 2022
    Assignees: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, TRAVERE THERAPEUTICS SWITZERLAND GMBH
    Inventors: Tomas Majtan, Jan P. Kraus, Erez M. Bublil, Frank Glavin, Marcia Sellos-Moura
  • OPTIMIZATION OF ENZYME REPLACEMENT THERAPY FOR TREATMENT OF HOMOCYSTINURIA
    Publication number: 20200261555
    Abstract: The present invention provides a method of PEGylating a human truncated cystathionine ?-synthase protein containing a mutation of a cysteine to a serine at amino acid position 15 (htCBS C15S). The htCBS C15S was PEGylated with one of 5 kDa, 10 kDa, or 20 kDa NHS ester PEG molecules. In-process monitoring of the PEGylation process was used in the method to reduce levels of unPEGylated htCBS C15S and htCBS C15S with insufficient PEGylation. Administration of the PEGylated htCBS C15S had efficacy throughout the course of treatment for homocystinuria.
    Type: Application
    Filed: April 17, 2018
    Publication date: August 20, 2020
    Inventors: Tomas Majtan, Jan P. Kraus, Erez M. Bublil, Frank Glavin, Marcia Sellos-Moura